NZ708537A - Method for the preparation of human albumin with reduced level of dissolved oxygen - Google Patents

Method for the preparation of human albumin with reduced level of dissolved oxygen

Info

Publication number
NZ708537A
NZ708537A NZ708537A NZ70853715A NZ708537A NZ 708537 A NZ708537 A NZ 708537A NZ 708537 A NZ708537 A NZ 708537A NZ 70853715 A NZ70853715 A NZ 70853715A NZ 708537 A NZ708537 A NZ 708537A
Authority
NZ
New Zealand
Prior art keywords
preparation
dissolved oxygen
human albumin
reduced level
albumin
Prior art date
Application number
NZ708537A
Other languages
English (en)
Inventor
Nieto Juan Ignacio Jorquera
Rierola Montserrat Costa
Fernandez Ana Maria Ortiz
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ708537(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of NZ708537A publication Critical patent/NZ708537A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ708537A 2014-05-29 2015-05-27 Method for the preparation of human albumin with reduced level of dissolved oxygen NZ708537A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430824A ES2524516B1 (es) 2014-05-29 2014-05-29 Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Publications (1)

Publication Number Publication Date
NZ708537A true NZ708537A (en) 2017-06-30

Family

ID=52003454

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ708537A NZ708537A (en) 2014-05-29 2015-05-27 Method for the preparation of human albumin with reduced level of dissolved oxygen

Country Status (22)

Country Link
US (1) US10350274B2 (OSRAM)
EP (1) EP2952203B9 (OSRAM)
JP (3) JP2015224251A (OSRAM)
KR (1) KR101960729B1 (OSRAM)
CN (1) CN105315362B (OSRAM)
AR (1) AR100618A1 (OSRAM)
AU (1) AU2015202413B2 (OSRAM)
BR (1) BR102015012091A8 (OSRAM)
CA (1) CA2890642C (OSRAM)
CL (1) CL2015001446A1 (OSRAM)
ES (2) ES2524516B1 (OSRAM)
HU (1) HUE031823T2 (OSRAM)
IL (1) IL238898B (OSRAM)
MX (1) MX362869B (OSRAM)
MY (1) MY171771A (OSRAM)
NZ (1) NZ708537A (OSRAM)
PL (1) PL2952203T3 (OSRAM)
PT (1) PT2952203T (OSRAM)
RU (1) RU2657578C2 (OSRAM)
SG (1) SG10201504137PA (OSRAM)
TW (1) TWI607018B (OSRAM)
ZA (1) ZA201503539B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
ES2975517T3 (es) 2016-04-28 2024-07-08 Alkahest Inc Fracciones de plasma como terapia para el cáncer de timo
SG11201901273TA (en) 2016-08-18 2019-03-28 Alkahest Inc Blood plasma fractions as a treatment for aging-associated cognitive disorders
CN117899111A (zh) 2017-04-26 2024-04-19 万能溶剂有限公司 用血浆和血浆制品治疗认知障碍和运动障碍的给药方案
KR20210024196A (ko) 2018-07-20 2021-03-04 알카헤스트 인코포레이티드 혈장 및 혈장 산물로 인지 및 운동 장애를 치료하기 위한 투여 요법
UA128648C2 (uk) 2018-10-26 2024-09-18 Алкахест, Інк. Застосування плазми крові та фракцій плазми для пом'якшення болю, поліпшення загоювання ран та післяопераційного відновлення
CN109627322A (zh) * 2019-01-07 2019-04-16 中国科学院过程工程研究所 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法
CA3151943A1 (en) 2019-11-04 2021-05-14 Viktoria Kheifets Blood plasma fractions for use in muscle regeneration
EP4061384A4 (en) 2019-11-20 2023-11-01 Alkahest, Inc. BLOOD PLASMA FRACTIONS FOR USE IN LIVER REGENERATION
JP2026511640A (ja) 2023-03-29 2026-04-14 グリフォルス・ワールドワイド・オペレーションズ・リミテッド FcεRIβ自己抗体のレベルが低減された血漿製剤の組成物および調製方法
CN118166053B (zh) * 2024-03-15 2025-02-07 通化安睿特生物制药股份有限公司 一种制备低o-糖基化水平的重组人白蛋白的方法
WO2025230830A1 (en) 2024-04-29 2025-11-06 Alkahest, Inc. Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4094965A (en) * 1977-04-01 1978-06-13 New England Nuclear Corporation Diagnostic agents containing albumin and method for making same
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
JPH07126182A (ja) * 1993-10-27 1995-05-16 Green Cross Corp:The 組換えヒト血清アルブミン製剤の滅菌方法
SE9402119D0 (sv) * 1994-06-16 1994-06-16 Pharmacia Ab Solution
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP4254117B2 (ja) * 2001-03-27 2009-04-15 ニプロ株式会社 アルブミン溶液収容プラスチック容器
DE60234142D1 (de) * 2001-03-27 2009-12-10 Nipro Corp Albuminlösung enthaltender Kunststoffbehälter
JP4225416B2 (ja) * 2001-06-29 2009-02-18 旭化成ファーマ株式会社 タンパク質製剤の安定性を改善する方法
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
ATE342904T1 (de) * 2003-08-28 2006-11-15 Nipro Corp Künstlicher sauerstoffträger und herstellungsverfahren dafür
RS52459B (sr) * 2006-02-07 2013-02-28 Shire Human Genetic Therapies Inc. Stabilizovane kompozicije glukocerebrozidaze
ES2294976B1 (es) * 2007-11-12 2008-12-16 Grifols, S.A. "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion".
JP5990880B2 (ja) * 2011-08-31 2016-09-14 東レ株式会社 有用タンパク質組成物およびその製造方法
CN102816230B (zh) * 2012-08-27 2014-02-12 同路生物制药股份有限公司 人血白蛋白的制备方法
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido

Also Published As

Publication number Publication date
RU2657578C2 (ru) 2018-06-14
PT2952203T (pt) 2016-11-23
CA2890642A1 (en) 2015-11-29
JP2018115210A (ja) 2018-07-26
CN105315362A (zh) 2016-02-10
MX362869B (es) 2019-02-20
KR101960729B1 (ko) 2019-03-21
US20170000855A9 (en) 2017-01-05
ZA201503539B (en) 2017-01-25
EP2952203B1 (en) 2016-10-26
ES2524516B1 (es) 2015-03-31
BR102015012091A8 (pt) 2021-03-16
KR20160024348A (ko) 2016-03-04
CN105315362B (zh) 2019-10-25
HUE031823T2 (en) 2017-08-28
BR102015012091A2 (pt) 2016-01-05
JP2020111614A (ja) 2020-07-27
AU2015202413B2 (en) 2017-08-31
CL2015001446A1 (es) 2016-05-13
TWI607018B (zh) 2017-12-01
CA2890642C (en) 2019-02-12
MX2015006407A (es) 2015-11-30
AR100618A1 (es) 2016-10-19
MY171771A (en) 2019-10-29
US10350274B2 (en) 2019-07-16
IL238898B (en) 2018-01-31
EP2952203A1 (en) 2015-12-09
PL2952203T3 (pl) 2017-02-28
US20150343025A1 (en) 2015-12-03
RU2015118453A (ru) 2016-12-10
EP2952203B9 (en) 2018-03-14
JP2015224251A (ja) 2015-12-14
AU2015202413A1 (en) 2015-12-17
ES2601137T3 (es) 2017-02-14
ES2524516A1 (es) 2014-12-09
SG10201504137PA (en) 2015-12-30
TW201544510A (zh) 2015-12-01

Similar Documents

Publication Publication Date Title
MX2015006407A (es) Procedimiento de preparacion de albumina humana con nivel de oxigeno disuelto reducido.
EA033286B1 (ru) Способ лечения или отсрочки развития хронической болезни почек
EA201791182A1 (ru) Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
PH12016502150A1 (en) Method for treating renal cell carcimona
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
PH12016500158A1 (en) Methods for controlling fucosylation levels in proteins
EA201791467A1 (ru) Водный офтальмологический раствор
PH12016502322B1 (en) Compounds and methods for preventing or treating malaria
MX2015008310A (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
PH12017500563A1 (en) Stabilized adrenomedullin derivatives and use thereof
EA201791845A1 (ru) Твердые формы менахинолов
NZ722725A (en) Flavour stable beverages
MX374865B (es) Solución de diálisis.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
MY188930A (en) Treatment process of gas containing zero-valent mercury and mercury separation system
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
EE201400004A (et) Meetod kõrge aktiivkloori sisaldusega desinfektsioonivahendi saamiseks läbivoolu diafragmaelektrolüüserist
MX361559B (es) Metodo para tratar limo de anodo de plomo.
UA79303U (ru) Применение таурина как средства стабилизации концентрации итраконазола в плазме крови при лечении грибковых заболеваний
UY36507A (es) Procedimiento de preparacion de albumina humana con nivel de oxigeno disuelto reducido
TH165188A (th) วิธีการสำหรับการเตรียมอัลบูมินมนุษย์ที่มีระดับของออกซิเจนที่ได้ละลายอยู่ลดลง
UA105659U (uk) Застосування способу визначення вмісту теофіліну як способу визначення концентрації елетриптану у водному розчині
UA91071U (uk) Спосіб профілактики та корекції запальних хвороб на донозологічному рівні
EA201700030A1 (ru) Липид, содержащий докозапентаеновую кислоту
GB2546703A (en) Compounds

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2020 BY AJ PARK

Effective date: 20190227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2021 BY AJ PARK

Effective date: 20200311

LAPS Patent lapsed